198 related articles for article (PubMed ID: 33745983)
1. GPR55 in the brain and chronic neuropathic pain.
Armin S; Muenster S; Abood M; Benamar K
Behav Brain Res; 2021 May; 406():113248. PubMed ID: 33745983
[TBL] [Abstract][Full Text] [Related]
2. Contribution of G Protein-Coupled Receptor 55 to Periaqueductal Gray-Mediated Antinociception in the Inflammatory Pain.
Blanton H; Armin S; Muenster S; Abood M; Benamar K
Cannabis Cannabinoid Res; 2022 Jun; 7(3):274-278. PubMed ID: 35612493
[TBL] [Abstract][Full Text] [Related]
3. Blockade of GPR55 in dorsal periaqueductal gray produces anxiety-like behaviors and evocates defensive aggressive responses in alcohol-pre-exposed rats.
Vázquez-León P; Miranda-Páez A; Calvillo-Robledo A; Marichal-Cancino BA
Neurosci Lett; 2021 Nov; 764():136218. PubMed ID: 34487839
[TBL] [Abstract][Full Text] [Related]
4. GPR18-NAGly system in periaqueductal gray and chronic neuropathic pain.
Narasimhan M; Mahimainathan L; Reddy PH; Benamar K
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165974. PubMed ID: 32949767
[No Abstract] [Full Text] [Related]
5. Medial prefrontal cortex diclofenac-induced antinociception is mediated through GPR55, cannabinoid CB1, and mu-opioid receptors of this area and periaqueductal gray.
Tamaddonfard E; Erfanparast A; Salighedar R; Tamaddonfard S
Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):371-379. PubMed ID: 31641818
[TBL] [Abstract][Full Text] [Related]
6. The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray.
Deliu E; Sperow M; Console-Bram L; Carter RL; Tilley DG; Kalamarides DJ; Kirby LG; Brailoiu GC; Brailoiu E; Benamar K; Abood ME
Mol Pharmacol; 2015 Aug; 88(2):265-72. PubMed ID: 25972448
[TBL] [Abstract][Full Text] [Related]
7. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
8. Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.
Palazzo E; Luongo L; Bellini G; Guida F; Marabese I; Boccella S; Rossi F; Maione S; de Novellis V
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):148-61. PubMed ID: 22483283
[TBL] [Abstract][Full Text] [Related]
9. Role of midbrain periaqueductal gray P2X3 receptors in electroacupuncture-mediated endogenous pain modulatory systems.
Xiao Z; Ou S; He WJ; Zhao YD; Liu XH; Ruan HZ
Brain Res; 2010 May; 1330():31-44. PubMed ID: 20302849
[TBL] [Abstract][Full Text] [Related]
10. Region-specific deletions of the glutamate transporter GLT1 differentially affect nerve injury-induced neuropathic pain in mice.
Zhao Z; Hiraoka Y; Ogawa H; Tanaka K
Glia; 2018 Sep; 66(9):1988-1998. PubMed ID: 29722912
[TBL] [Abstract][Full Text] [Related]
11. WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms.
Wen J; Jones M; Tanaka M; Selvaraj P; Symes AJ; Cox B; Zhang Y
J Neuroinflammation; 2018 Jan; 15(1):9. PubMed ID: 29310667
[TBL] [Abstract][Full Text] [Related]
12. Antihyperalgesic effect of 5-HT7 receptor activation on the midbrain periaqueductal gray in a rat model of neuropathic pain.
Li SF; Zhang YY; Li YY; Wen S; Xiao Z
Pharmacol Biochem Behav; 2014 Dec; 127():49-55. PubMed ID: 25450118
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Sharir H; Abood ME
Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
[TBL] [Abstract][Full Text] [Related]
14. Impairment of adenylyl cyclase-mediated glutamatergic synaptic plasticity in the periaqueductal grey in a rat model of neuropathic pain.
Ho YC; Cheng JK; Chiou LC
J Physiol; 2015 Jul; 593(13):2955-73. PubMed ID: 25868084
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HCN channels within the periaqueductal gray attenuates neuropathic pain in rats.
Du L; Wang SJ; Cui J; He WJ; Ruan HZ
Behav Neurosci; 2013 Apr; 127(2):325-9. PubMed ID: 23398435
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent plasticity in endocannabinoid modulation of pain processing through postnatal development.
Kwok CH; Devonshire IM; Imraish A; Greenspon CM; Lockwood S; Fielden C; Cooper A; Woodhams S; Sarmad S; Ortori CA; Barrett DA; Kendall D; Bennett AJ; Chapman V; Hathway GJ
Pain; 2017 Nov; 158(11):2222-2232. PubMed ID: 28767505
[TBL] [Abstract][Full Text] [Related]
17. Glial activation in the periaqueductal gray promotes descending facilitation of neuropathic pain through the p38 MAPK signaling pathway.
Ni HD; Yao M; Huang B; Xu LS; Zheng Y; Chu YX; Wang HQ; Liu MJ; Xu SJ; Li HB
J Neurosci Res; 2016 Jan; 94(1):50-61. PubMed ID: 26423029
[TBL] [Abstract][Full Text] [Related]
18. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
[TBL] [Abstract][Full Text] [Related]
19. Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats.
Liu S; Xu C; Li G; Liu H; Xie J; Tu G; Peng H; Qiu S; Liang S
Neurochem Int; 2012 May; 60(6):565-72. PubMed ID: 22361062
[TBL] [Abstract][Full Text] [Related]
20. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
